Erectile Dysfunct Rx denials in California external review

In the California DMHC record, independent physician reviewers decided 13 published external-review cases involving Erectile Dysfunct Rxand overturned the plan’s denial in 53.8%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
13
2019–2025
Overturned
53.8%
7 denials reversed

Conditions behind Erectile Dysfunct Rx denials

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
Prostate Problem5
60%
Erectile Dysfunction4
50%
Typical time to a decision
11 days
Most land between 10 and 21 days
Handled as urgent
23.1%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient has a history of BPH (benign prostatic hyperplasia). The patient’s symptoms include urinary hesitancy and nocturia. The patient has been treated with Flomax but found that it was bothersome to his premature ejaculation. His premature ejaculation has been a lifelong problem. The patient has also been treated with Rapaflo but stopped using it due to the cost; the medication was noted to improve his symptoms. The provider recommended Tadalafil tablet 5 mg. The Health Plan indicates that the requested medication is not medically necessary for the treatment of the patient’s medical condition. At issue in this case is whether Tadalafil tablet 5 mg is medically necessary for the treatment of this patient.
Medical Necessity · 2022 · IMR MN22-37733
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for a dosing regimen for the medication, Cialis. Findings: The U.S. Food and Drug Administration (FDA) approves the use of Cialis (generic name tadalafil) for the treatment of erectile dysfunction (ED). A study notes that in a randomized, double-blind study of patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH), treatment satisfaction was greater with tadalafil over placebo. The authors further found that in patients with LUTS from BPH, tadalafil improved flow rates by 2.4 mL per second, compared with an improvement of around 2.2 mL per second with alpha blockers such as tamsulosin.
Medical Necessity · 2021 · IMR MN21-34721

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting reimbursement and authorization and coverage for the daily use of Cialis (Tadalafil). The enrollee has prostate pain, initially seen with complaints of bladder pressure, constipation, fatigue, nocturia, sexual dysfunction, urinary frequency and urinary urgency. Cialis was prescribed. A follow up visit indicated symptoms had improved with Kegel exercises. The enrollee did not want to take Finasteride or similar medications due to risk of impotence on the side effects list. He was experiencing sexual dysfunction, urinary dribbling and urinary frequency. Review of the enrollee’s active medications in the record shows the provider prescribed Finasteride tablet. The provider’s assessment/plan on a follow up visit indicates the enrollee requested Cialis.
Medical Necessity · 2019 · IMR MN19-31695
Nature of Statutory Criteria/Case Summary: The parent of an enrollee has requested authorization and coverage for sildenafil. One study demonstrated no favorable significance of sildenafil in improving maximal oxygen consumption in patients with Fontan circulation. Although the patient has a condition where elevated pulmonary vascular pressures and resistance are detrimental, there is a lack of a recent diagnostic study for this patient which has demonstrated pulmonary hypertension. In fact, the most recent cardiac catheterization demonstrated normal pulmonary artery pressures. Moreover, the patient is asymptomatic per the provider’s records with normal oxygen saturation on room air.
Experimental/Investigational · 2023 · IMR EI23-39842

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Erectile Dysfunct Rx, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Denied Erectile Dysfunct Rx? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9